Bellicum Logo.jpg
Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update
November 06, 2019 16:15 ET | Bellicum Pharmaceuticals, Inc.
Raised gross proceeds of $69.6 million from public offering and private placement option fee Narrowed strategic focus to core GoCAR-T® cell therapy programs Cost saving initiatives underway to...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019
October 31, 2019 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
October 30, 2019 07:30 ET | Bellicum Pharmaceuticals, Inc.
- Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT -   HOUSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM),...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2019 16:07 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Logo.jpg
CORRECTING and REPLACING - Bellicum Pharmaceuticals, Inc.
August 16, 2019 10:52 ET | Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement Pricing of $57.5 Million Public Offering of Preferred Stock and Warrants and Entry into Concurrent...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Announces Pricing of Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement
August 16, 2019 08:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Provides Interim Data for BPX-601 in Patients with Metastatic Pancreatic Cancer for Presentation at ASCO Annual Meeting
June 01, 2019 09:00 ET | Bellicum Pharmaceuticals, Inc.
Data provides further evidence that GoCAR-T® technology boosts expansion and persistence of therapeutic T cells in patients T cell expansion and persistence greater in patients who received...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2019 16:14 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
May 29, 2019 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Present Updated Results for BPX-601 at the 2019 ASCO Annual Meeting
May 15, 2019 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, May 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...